BMP7

Summary

BMP7 (bone morphogenetic protein 7, HGNC:1074) is a protein-coding gene on chromosome 20q13.31, encoding Bone morphogenetic protein 7 (P18075). Growth factor of the TGF-beta superfamily that plays important role in various biological processes, including embryogenesis, hematopoiesis, neurogenesis and skeletal morphogenesis.

This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer, which plays a role in bone, kidney and brown adipose tissue development. Additionally, this protein induces ectopic bone formation and may promote fracture healing in human patients.

Source: NCBI Gene 655 — RefSeq curated summary.

At a glance

• Gene–disease (curated): multiple congenital anomalies/dysmorphic syndrome (Moderate, GenCC) — +4 more curated relationships
• GWAS associations: 23
• Clinical variants (ClinVar): 140 total — 2 pathogenic
• Transcription factor: yes — 10 downstream targets (CollecTRI)
• MANE Select transcript: NM_001719

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1074
Approved symbol	BMP7
Name	bone morphogenetic protein 7
Location	20q13.31
Locus type	gene with protein product
Status	Approved
Aliases	OP-1
Ensembl gene	ENSG00000101144
Ensembl biotype	protein_coding
OMIM	112267
Entrez	655

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 4 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000395863, ENST00000395864, ENST00000433911, ENST00000450594, ENST00000460817, ENST00000463939, ENST00000476877, ENST00000524700, ENST00000530870

RefSeq mRNA: 1 — MANE Select: NM_001719 NM_001719

CCDS: CCDS13455

Canonical transcript exons

ENST00000395863 — 7 exons

Exon	Start	End
ENSE00001523115	57168753	57171108
ENSE00001908937	57265705	57266641
ENSE00003463644	57228229	57228421
ENSE00003586843	57202475	57202623
ENSE00003601695	57183722	57183919
ENSE00003614759	57174931	57175007
ENSE00003620144	57173200	57173310

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 97.34.

FANTOM5 (CAGE): breadth broad, TPM avg 18.7444 / max 326.3417, expressed in 599 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188100	11.9953	566
188098	3.9152	512
188097	1.6663	463
188096	0.5525	283
188099	0.3044	177
209174	0.1707	110
188095	0.1401	75

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	97.34	gold quality
ventricular zone	UBERON:0003053	96.79	gold quality
endometrium epithelium	UBERON:0004811	94.32	gold quality
cranial nerve II	UBERON:0000941	93.71	gold quality
ganglionic eminence	UBERON:0004023	91.83	gold quality
olfactory bulb	UBERON:0002264	89.64	silver quality
thyroid gland	UBERON:0002046	89.41	gold quality
pancreatic ductal cell	CL:0002079	89.19	silver quality
left lobe of thyroid gland	UBERON:0001120	88.98	gold quality
right lobe of thyroid gland	UBERON:0001119	88.79	gold quality
buccal mucosa cell	CL:0002336	88.73	silver quality
esophagus mucosa	UBERON:0002469	87.61	gold quality
type B pancreatic cell	CL:0000169	87.49	gold quality
caudate nucleus	UBERON:0001873	87.37	gold quality
amygdala	UBERON:0001876	86.97	gold quality
medial globus pallidus	UBERON:0002477	86.90	gold quality
sural nerve	UBERON:0015488	86.59	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.35	gold quality
nucleus accumbens	UBERON:0001882	85.83	gold quality
skin of leg	UBERON:0001511	85.52	gold quality
putamen	UBERON:0001874	85.25	gold quality
embryo	UBERON:0000922	84.94	gold quality
spinal cord	UBERON:0002240	84.78	gold quality
skin of abdomen	UBERON:0001416	84.48	gold quality
gingival epithelium	UBERON:0001949	84.28	gold quality
placenta	UBERON:0001987	84.22	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	83.93	gold quality
globus pallidus	UBERON:0001875	83.78	gold quality
Ammon’s horn	UBERON:0001954	83.73	gold quality
zone of skin	UBERON:0000014	83.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-36552	no	63.56
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

10 targets.

Target	Regulation
DLK1	Unknown
HAS2	Activation
HYAL1	Repression
HYAL2	Repression
MMP13	Repression
NEUROG2	Activation
PPARG	Activation
PPARGC1A	Unknown
PRDM16	Unknown
UCP1	Unknown

Upstream regulators (CollecTRI, top): BMP4, GLI2, HAND2, HDAC2, HOXA13, LDB1, LMO4, NFATC1, SMAD1, SP1, TCF4, TP53, VDR, YBX1

miRNA regulators (miRDB)

77 targeting BMP7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-432-3P	100.00	67.86	705
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4534	99.99	66.58	1907
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-12124	99.68	69.17	2700

Literature-anchored findings (GeneRIF, showing 40)

• Transforming growth factor-beta1 supports the rapid morphogenesis of heterotopic endochondral bone initiated by human osteogenic protein-1 via the synergistic upregulation of molecular markers (PMID:11769973)
• age related decline in level may contribute to the elevated susceptibility of cartilage to the degenerative process. (PMID:12385776)
• crystal structure of the antagonist Noggin bound to BMP-7, which shows that Noggin inhibits BMP signalling by blocking the molecular interfaces of the binding epitopes for both type I and type II receptors (PMID:12478285)
• BMP-7 signaling is inhibited by glypican 3 in hepatocellular carcinoma cells (PMID:12478660)
• BMP-7 inhibits constitutive and IL-1 beta-induced expression of monocyte chemoattractant protein-1 in mesangial cells, partly through suppression of c-Jun N-terminal kinase activity and AP-1 binding activity. (PMID:12594282)
• crystal structure of BMP7 in complex with the extracellular domain (ECD) of the activin type II receptor (PMID:12667445)
• IGF-1 and OP-1 could be key physiological regulators of MMP-13 gene expression (PMID:12734180)
• In pulmonary artery smooth muscle cells from pulmonary hypertension patients, the BMP-2- or BMP-7-induced apoptosis was significantly inhibited compared with PASMCs from patients with secondary pulmonary hypertension. (PMID:12740218)
• BMP-7 is expressed in various breast cancer cell lines in a cell line-specific manner (PMID:12792780)
• BMP-7 plays an important role in the regulation of anti-inflammatory response in the adult gut tissue. (PMID:12811818)
• Overall decrease in endogenous OP-1 in degenerated and OA tissue suggests that OP-1 could be one of the factors responsible for normal homeostasis and matrix integrity in cartilage. (PMID:12919879)
• Modulation of endogenous osteogenic protein-1 (OP-1) by interleukin-1 in adult human articular cartilage. (PMID:12925612)
• OP-1 stimulated cell proliferation and mRNA expression of several biochemical markers in this ligament cell culture model (PMID:14587033)
• In the extraskeletal model, newly formed bone was evident in the presence of rhBMP-7 (PMID:14751565)
• results suggest expression of the Ihh gene, which contains multiple Smad binding sites, may be finely regulated by a gradient of bone morphogenetic protein BMP7 (PMID:14981086)
• Stimulation of kidney cells with BMP-7 induced hyaluronan synthase 2 mRNA expression and decreased the expression of Hyal1 and Hyal2. (PMID:15100360)
• The effect of BMP-7 on TGF-beta1 synthesis in TNF-alpha-stimulated cells was abrogated by disruption of CD44-hyaluronan interactions, suggesting that it was due to increased monocyte binding to hyaluronan on the cell surface. (PMID:15574511)
• To analyze the expression of bone morphogenetic proteins (BMPs) in prostate and breast cancers with established metastasis in bone (PMID:15861517)
• the prodomain of BMP-7 has a role in targeting the BMP-7 complex to the extracellular matrix (PMID:15929982)
• BMP7 induced Smad phosphorylation in a dose-dependent manner, with Smad activation clearly demonstrable in prostate adenocarcinoma. (PMID:15994952)
• BMPs influence the formation of the osteolytic prostate cancer metastases, and treatment modalities that inhibit BMP activity may limit the progression of the lytic component of prostate cancer metastases. (PMID:16126463)
• Our results are suggesting a possible functional role for BMP7 in breast cancer development. (PMID:16419056)
• Measurement of OP-1 in joint fluid may have value in the clinical evaluation of joint diseases. (PMID:16646979)
• BMP7 could restore the homeostatic balance of pSmad signaling found in normal kidneys, thereby preventing or reversing the development of chronic allograft nephropathy. (PMID:16686760)
• Topical and differential expression of BMP-2/4 and BMP-7 mRNA and protein was found in bursa tissue. (PMID:16719933)
• BMP-7 expression in the adult human kidney appears to be more restricted than in the fetal situation and predominantly found in the distal nephron. (PMID:16807538)
• Osteogenic protein-1 (OP-1 has shown particular potential in clinical trials as a bone graft substitute . (PMID:16831023)
• Recombinant human BMP-7 plays a role in the migration of bone-forming cells. (PMID:16846353)
• maintenance of renal BMP-7 during the evolution of diabetic nephropathy reduces diabetic renal injury, especially podocyte dropout. The findings also establish a role for endogenous glomerular BMP-7 as an autocrine regulator of podocyte integrity in vivo. (PMID:16899516)
• BMP7 expression was almost completely absent at the invasive margin of esophageal tumors, but present in the central area. It may antagonize TGF-beta1’s role in invasiveness. (PMID:17018615)
• strong BMP staining is seen in maturing chondrocytes, and thus may play a role in chondrocyte differentiation and/or apoptosis; BMP release by osteoclasts may promote osteoblastic differentiation at sites of bone remodeling (PMID:17262821)
• These results indicate that mutations are rare in FGF8 and FGFR2 in hypospadias, but gene variants may influence the risk. (PMID:17264867)
• Immunohistochemistry of cirrhotic human liver demonstrated upregulated BMP7 protein expression in hepatocytes as compared with normal human liver. (PMID:17415633)
• Proinvasive activity of BMP7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells is reported. (PMID:17478078)
• BMP7 promotes the adipogenic and not the osteogenic or chondrogenic lineage development of human stem cells (PMID:17497692)
• induction of BMP7 expression is frequent in melanomas and may serve as a novel prognostic marker of progression in melanoma patients (PMID:17522432)
• BMP-7 was more potent than BMP-2 in inducing chondrogenesis, but the properties of the differentiated tissue were similar in each case (PMID:17530715)
• The presence of BMP-7 and IL-1Ra antagonized the anti-anabolic effects of lipopolysaccharide (PMID:17530716)
• Expression of BMP-4 and BMP-7 and their receptors in human ovaries from fetuses as well as adults. (PMID:17624341)
• Approximately half of the prostate tumors displayed increased copy numbers of the BMP2, BMP5, BMP7, and UC28 gene loci, which may account for their abnormal gene expression patterns in neoplastic prostate tissue. (PMID:17656261)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	bmp7a	ENSDARG00000018260
danio_rerio	bmp7b	ENSDARG00000063230
mus_musculus	Bmp7	ENSMUSG00000008999
rattus_norvegicus	Bmp7	ENSRNOG00000053384

Paralogs (31): TGFB2 (ENSG00000092969), TGFB1 (ENSG00000105329), BMP5 (ENSG00000112175), BMP8B (ENSG00000116985), TGFB3 (ENSG00000119699), INHBA (ENSG00000122641), INHA (ENSG00000123999), BMP4 (ENSG00000125378), BMP2 (ENSG00000125845), GDF5 (ENSG00000125965), GDF1 (ENSG00000130283), BMP15 (ENSG00000130385), GDF15 (ENSG00000130513), GDF11 (ENSG00000135414), MSTN (ENSG00000138379), INHBE (ENSG00000139269), LEFTY2 (ENSG00000143768), GDF7 (ENSG00000143869), BMP3 (ENSG00000152785), BMP6 (ENSG00000153162), GDF6 (ENSG00000156466), NODAL (ENSG00000156574), INHBB (ENSG00000163083), BMP10 (ENSG00000163217), GDF9 (ENSG00000164404), INHBC (ENSG00000175189), BMP8A (ENSG00000183682), GDF3 (ENSG00000184344), LEFTY1 (ENSG00000243709), GDF2 (ENSG00000263761), GDF10 (ENSG00000266524)

Protein

Protein identifiers

Bone morphogenetic protein 7 — P18075 (reviewed: P18075)

Alternative names: Osteogenic protein 1

All UniProt accessions (5): P18075, A8K571, B1AKZ9, B1AL00, H0Y4B5

UniProt curated annotations — full annotation on UniProt →

Function. Growth factor of the TGF-beta superfamily that plays important role in various biological processes, including embryogenesis, hematopoiesis, neurogenesis and skeletal morphogenesis. Initiates the canonical BMP signaling cascade by associating with type I receptor ACVR1 and type II receptor ACVR2A. Once all three components are bound together in a complex at the cell surface, ACVR2A phosphorylates and activates ACVR1. In turn, ACVR1 propagates signal by phosphorylating SMAD1/5/8 that travel to the nucleus and act as activators and repressors of transcription of target genes. For specific functions such as growth cone collapse in developing spinal neurons and chemotaxis of monocytes, also uses BMPR2 as type II receptor. Can also signal through non-canonical pathways such as P38 MAP kinase signaling cascade that promotes brown adipocyte differentiation through activation of target genes, including members of the SOX family of transcription factors. Promotes the expression of HAMP, this is repressed by its interaction with ERFE.

Subunit / interactions. Homodimer; disulfide-linked. Interacts with SOSTDC1. Interacts with TWSG1. Interacts with FBN1 (via N-terminal domain) and FBN2. Interacts with type I receptor ACVR1. Interacts with type II receptor ACVR2A. Interacts with NOG; this interaction inhibits canonical BMP signaling. Interacts with SCUBE3. Interacts with ERFE; the interaction inhibits BMP-induced transcription of HAMP. Interacts with TGFBR3.

Subcellular location. Secreted.

Tissue specificity. Expressed in the kidney and bladder. Lower levels seen in the brain.

Post-translational modifications. Several N-termini starting at positions 293, 300, 315 and 316 have been identified by direct sequencing resulting in secretion of different mature forms.

Similarity. Belongs to the TGF-beta family.

RefSeq proteins (1): NP_001710* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001111	TGF-b_propeptide	Domain
IPR001839	TGF-b_C	Domain
IPR015615	TGF-beta-like	Family
IPR017948	TGFb_CS	Conserved_site
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF00019, PF00688

UniProt features (28 total): strand 8, disulfide bond 4, helix 4, glycosylation site 4, sequence variant 2, turn 2, signal peptide 1, propeptide 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
1LXI	X-RAY DIFFRACTION	2
1M4U	X-RAY DIFFRACTION	2.42
1BMP	X-RAY DIFFRACTION	2.8
1LX5	X-RAY DIFFRACTION	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P18075-F1	76.50	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 363–430, 395, 330–396, 359–428

Glycosylation sites (4): 187, 302, 321, 372

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-2129379	Molecules associated with elastic fibres
R-HSA-9844594	Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
R-HSA-1266738	Developmental Biology
R-HSA-1474244	Extracellular matrix organization
R-HSA-1566948	Elastic fibre formation
R-HSA-9843743	Transcriptional regulation of brown and beige adipocyte differentiation
R-HSA-9843745	Adipogenesis

MSigDB gene sets: 553 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_DENDRITE_DEVELOPMENT, GOBP_LABYRINTHINE_LAYER_DEVELOPMENT, GOBP_HINDBRAIN_DEVELOPMENT, E2F_Q4_01, GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_CELL_MIGRATION_INVOLVED_IN_HEART_DEVELOPMENT, LEE_NEURAL_CREST_STEM_CELL_DN, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION

GO Biological Process (93): skeletal system development (GO:0001501), osteoblast differentiation (GO:0001649), metanephros development (GO:0001656), ureteric bud development (GO:0001657), mesoderm formation (GO:0001707), mesonephros development (GO:0001823), epithelial to mesenchymal transition (GO:0001837), endocardial cushion formation (GO:0003272), pericardium morphogenesis (GO:0003344), axon guidance (GO:0007411), heart development (GO:0007507), embryonic pattern specification (GO:0009880), positive regulation of gene expression (GO:0010628), negative regulation of striated muscle cell apoptotic process (GO:0010664), positive regulation of epithelial to mesenchymal transition (GO:0010718), dendrite development (GO:0016358), neural fold elevation formation (GO:0021502), embryonic limb morphogenesis (GO:0030326), positive regulation of bone mineralization (GO:0030501), BMP signaling pathway (GO:0030509), positive regulation of epithelial cell differentiation (GO:0030858), hindbrain development (GO:0030902), response to estradiol (GO:0032355), response to vitamin D (GO:0033280), positive regulation of heterotypic cell-cell adhesion (GO:0034116), ameloblast differentiation (GO:0036305), odontogenesis of dentin-containing tooth (GO:0042475), positive regulation of apoptotic process (GO:0043065), response to peptide hormone (GO:0043434), negative regulation of neuron differentiation (GO:0045665), positive regulation of neuron differentiation (GO:0045666), positive regulation of osteoblast differentiation (GO:0045669), negative regulation of Notch signaling pathway (GO:0045746), negative regulation of cell cycle (GO:0045786), negative regulation of mitotic nuclear division (GO:0045839), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), embryonic camera-type eye morphogenesis (GO:0048596), cardiac muscle tissue development (GO:0048738)

GO Molecular Function (7): cytokine activity (GO:0005125), growth factor activity (GO:0008083), heparin binding (GO:0008201), BMP receptor binding (GO:0070700), protein binding (GO:0005515), protein serine/threonine kinase activator activity (GO:0043539), receptor ligand activity (GO:0048018)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), vesicle (GO:0031982)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Elastic fibre formation	1
Transcriptional regulation of brown and beige adipocyte differentiation	1
Extracellular matrix organization	1
Adipogenesis	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
kidney development	2
anatomical structure formation involved in morphogenesis	2
receptor ligand activity	2
system development	1
ossification	1
cell differentiation	1
mesonephric tubule development	1
formation of primary germ layer	1
mesoderm morphogenesis	1
mesenchymal cell differentiation	1
endocardial cushion morphogenesis	1
morphogenesis of an epithelial sheet	1
embryonic morphogenesis	1
pericardium development	1
axonogenesis	1
neuron projection guidance	1
animal organ development	1
circulatory system development	1
pattern specification process	1
embryo development	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
negative regulation of muscle cell apoptotic process	1
striated muscle cell apoptotic process	1
regulation of striated muscle cell apoptotic process	1
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
positive regulation of cell differentiation	1
positive regulation of multicellular organismal process	1
neuron projection development	1
anatomical structure development	1
neural fold formation	1
limb morphogenesis	1
embryonic appendage morphogenesis	1
bone mineralization	1
regulation of bone mineralization	1
positive regulation of ossification	1
positive regulation of biomineral tissue development	1
cellular response to BMP stimulus	1

Protein interactions and networks

STRING

2952 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BMP7	NOG	Q13253	997
BMP7	BMPR2	Q13873	997
BMP7	BMPR1A	P36894	996
BMP7	ACVR1	Q04771	995
BMP7	ACVR2A	P27037	993
BMP7	BMPR1B	P78366	993
BMP7	FST	P19883	989
BMP7	ACVR2B	Q13705	985
BMP7	BMP2	P12643	975
BMP7	BMP4	P12644	953
BMP7	CHRD	Q9H2X0	900
BMP7	BMP8A	Q7Z5Y6	882
BMP7	BMP8B	P34820	879
BMP7	ADARB1	P78555	871
BMP7	FBN1	P35555	859

IntAct

74 interactions, top by confidence:

A	B	Type	Score
BMP7	TRIM27	psi-mi:“MI:0915”(physical association)	0.670
TRIM27	BMP7	psi-mi:“MI:0915”(physical association)	0.670
BMP7	KHDRBS2	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLC	BMP7	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP12-3	psi-mi:“MI:0915”(physical association)	0.560
BMP7	BEGAIN	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-3	BMP7	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP5-9	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	BMP7	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.560
BMP7	CCDC125	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP9-8	psi-mi:“MI:0915”(physical association)	0.560
BMP7	KRTAP3-1	psi-mi:“MI:0915”(physical association)	0.560
TRAC	COCH	psi-mi:“MI:0914”(association)	0.530
PLAUR	XRCC3	psi-mi:“MI:0914”(association)	0.530
PRG3	ZNF324	psi-mi:“MI:0914”(association)	0.530
BMP7	NOG	psi-mi:“MI:0407”(direct interaction)	0.440
BMP7	Acvr2a	psi-mi:“MI:0407”(direct interaction)	0.440
BMP7	CCNDBP1	psi-mi:“MI:0915”(physical association)	0.370
BMP7	MTUS2	psi-mi:“MI:0915”(physical association)	0.370
BMP7	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.370
BMP7	VWA8	psi-mi:“MI:0914”(association)	0.350
DKKL1	VWA8	psi-mi:“MI:0914”(association)	0.350
OLFM2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
OLFM4	DDX11L8	psi-mi:“MI:0914”(association)	0.350
PTPRK	MANBA	psi-mi:“MI:0914”(association)	0.350
TAZ	MANBA	psi-mi:“MI:0914”(association)	0.350
SLAMF1	RTCA	psi-mi:“MI:0914”(association)	0.350

BioGRID (108): BMP7 (Two-hybrid), KRTAP5-9 (Two-hybrid), TRIM27 (Two-hybrid), MTUS2 (Two-hybrid), KRTAP10-7 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), BMP7 (Affinity Capture-MS), BMP7 (Affinity Capture-MS), BMP7 (Affinity Capture-MS), UBR1 (Affinity Capture-MS), VWA8 (Affinity Capture-MS), GSTCD (Affinity Capture-MS)

ESM2 similar proteins: A8WCC4, O19011, O93449, P01137, P03970, P04088, P04202, P07200, P07995, P08476, P09529, P09531, P09533, P10600, P15203, P16047, P17125, P17246, P17247, P17491, P18075, P18331, P18341, P23359, P27092, P27093, P34820, P34821, P42917, P43032, P49002, P50414, P54831, P55102, P55103, P55104, P57785, Q04906, Q04998, Q04999

Diamond homologs: A1C2U3, A1C2U6, A1C2U7, A1C2V0, A1C2V5, A8E7N9, G5EEL5, O08689, O14793, O18828, O18830, O18831, O18836, O35312, O42220, O42221, O42222, O46576, O61643, O95390, O95393, P09534, P12644, P12645, P17491, P18075, P20722, P20863, P22003, P22004, P22444, P23359, P27091, P27539, P35621, P43026, P43027, P43028, P43029, P48970

SIGNOR signaling

25 interactions.

A	Effect	B	Mechanism
BMP7	up-regulates	ACTR2	binding
BMP7	“down-regulates quantity by repression”	DLK1	“transcriptional regulation”
BMP7	up-regulates	Brown_adipogenesis
BMP7	up-regulates	MAPK14
BMP7	“up-regulates quantity by expression”	PPARGC1A	“transcriptional regulation”
BMP7	“up-regulates quantity by expression”	PRDM16	“transcriptional regulation”
BMP7	“up-regulates quantity by expression”	UCP1	“transcriptional regulation”
BMP7	up-regulates	PRDM16	“transcriptional regulation”
BMP7	up-regulates	PPARGC1A	“transcriptional regulation”
BMP7	up-regulates	UCP1	“transcriptional regulation”
BMP7	down-regulates	DLK1	“transcriptional regulation”
BMP7	up-regulates	BMPR1A/1B/2	binding
BMP7	“up-regulates activity”	BMPR1A/1B/2	binding
BMP7	up-regulates	BMP7	binding
BMP7	“down-regulates quantity by repression”	MMP13	“transcriptional regulation”
BMP7	up-regulates	BMPR2	binding
BMP7	up-regulates	ACVR2A	binding
BMP7	up-regulates	ACVR2B	binding
BMP7	“up-regulates quantity by expression”	PPARG	“transcriptional regulation”
BMP7	up-regulates	ACVR1/BMPR2	binding
BMP7	up-regulates	ACVR1	binding
SOSTDC1	“down-regulates activity”	BMP7
SMAD1/4	“up-regulates quantity by expression”	BMP7	“transcriptional regulation”
NOG	“down-regulates activity”	BMP7	binding
SOX17/POU5F1	“up-regulates quantity by expression”	BMP7	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	7	11.5×	3e-04

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

140 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	73
Likely benign	25
Benign	34

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1702933	NM_001719.3(BMP7):c.254A>T (p.Asp85Val)	Pathogenic
1702934	NM_001719.3(BMP7):c.523C>T (p.Arg175Trp)	Pathogenic

SpliceAI

2055 predictions. Top by Δscore:

Variant	Effect	Δscore
20:57171105:GGACC:G	acceptor_loss	1.0000
20:57171106:GACC:G	acceptor_loss	1.0000
20:57171107:ACCTG:A	acceptor_loss	1.0000
20:57171108:CCT:C	acceptor_loss	1.0000
20:57171109:C:CC	acceptor_gain	1.0000
20:57171109:C:G	acceptor_loss	1.0000
20:57171110:T:C	acceptor_loss	1.0000
20:57171115:C:CT	acceptor_gain	1.0000
20:57171117:C:CT	acceptor_gain	1.0000
20:57173198:A:AC	donor_gain	1.0000
20:57173199:C:CC	donor_gain	1.0000
20:57173199:CCAG:C	donor_gain	1.0000
20:57173306:CAGTC:C	acceptor_gain	1.0000
20:57173309:TC:T	acceptor_gain	1.0000
20:57173309:TCC:T	acceptor_loss	1.0000
20:57173310:CC:C	acceptor_gain	1.0000
20:57173310:CCT:C	acceptor_loss	1.0000
20:57173311:C:CC	acceptor_gain	1.0000
20:57174925:CCTTA:C	donor_loss	1.0000
20:57174926:CTTAC:C	donor_loss	1.0000
20:57174927:TTACC:T	donor_loss	1.0000
20:57174928:TAC:T	donor_loss	1.0000
20:57174929:A:AT	donor_loss	1.0000
20:57175039:CCAG:C	acceptor_gain	1.0000
20:57175040:CAG:C	acceptor_gain	1.0000
20:57175041:A:T	acceptor_gain	1.0000
20:57183748:T:TA	donor_gain	1.0000
20:57202473:A:AC	donor_gain	1.0000
20:57202473:ACCAT:A	donor_gain	1.0000
20:57202474:C:CC	donor_gain	1.0000

AlphaMissense

2872 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:57170965:G:C	C430W	1.000
20:57170966:C:A	C430F	1.000
20:57170966:C:G	C430S	1.000
20:57170966:C:T	C430Y	1.000
20:57170967:A:G	C430R	1.000
20:57170967:A:T	C430S	1.000
20:57170969:C:T	G429D	1.000
20:57170970:C:A	G429C	1.000
20:57170970:C:G	G429R	1.000
20:57170971:A:C	C428W	1.000
20:57170972:C:A	C428F	1.000
20:57170972:C:G	C428S	1.000
20:57170972:C:T	C428Y	1.000
20:57170973:A:G	C428R	1.000
20:57170973:A:T	C428S	1.000
20:57170981:A:T	V425D	1.000
20:57171005:A:G	L417P	1.000
20:57171011:A:T	V415D	1.000
20:57171035:A:G	L407P	1.000
20:57171035:A:T	L407H	1.000
20:57171038:A:T	V406D	1.000
20:57171053:A:G	L401P	1.000
20:57171062:G:T	P398H	1.000
20:57171067:A:C	C396W	1.000
20:57171068:C:A	C396F	1.000
20:57171068:C:G	C396S	1.000
20:57171068:C:T	C396Y	1.000
20:57171069:A:G	C396R	1.000
20:57171069:A:T	C396S	1.000
20:57173201:A:G	L382P	1.000

dbSNP variants (sampled 300 via entrez): RS1000069852 (20:57256642 T>A,G), RS1000074303 (20:57225309 A>G), RS1000085727 (20:57219658 G>T), RS1000085941 (20:57180904 A>G), RS1000131296 (20:57245172 T>C), RS1000135703 (20:57254321 C>G), RS1000155338 (20:57220913 G>A), RS1000227383 (20:57213545 C>T), RS1000240693 (20:57216670 G>A), RS1000259280 (20:57252960 G>A), RS1000336983 (20:57247965 T>C), RS1000350194 (20:57256967 G>A), RS1000354552 (20:57192350 G>A), RS1000365857 (20:57174315 C>T), RS1000449807 (20:57185250 G>A)

Disease associations

OMIM: gene MIM:112267 | disease phenotypes: MIM:614429, MIM:615779, MIM:187500, MIM:614433, MIM:610805, MIM:616892, MIM:106700

GenCC curated gene-disease

Disease	Classification	Inheritance
multiple congenital anomalies/dysmorphic syndrome	Moderate	Autosomal dominant
hypospadias	Limited	Autosomal dominant
isolated craniosynostosis	Limited	Autosomal dominant
Mayer-Rokitansky-Kuster-Hauser syndrome	Limited	Autosomal dominant
congenital anomaly of kidney and urinary tract	Limited	Autosomal dominant

Mondo (11): ventricular septal defect 1 (MONDO:0013746), congenital heart defects, multiple types, 4 (MONDO:0014344), tetralogy of fallot (MONDO:0008542), atrial septal defect 8 (MONDO:0013750), congenital anomaly of kidney and urinary tract (MONDO:0019719), nephrotic syndrome, type 12 (MONDO:0014817), congenital total pulmonary venous return anomaly (MONDO:0007130), hypospadias (MONDO:0005345), multiple congenital anomalies/dysmorphic syndrome (MONDO:0019042), isolated craniosynostosis (MONDO:0015337), Mayer-Rokitansky-Kuster-Hauser syndrome (MONDO:0017771)

Orphanet (5): Tetralogy of Fallot (Orphanet:3303), Interatrial communication (Orphanet:1478), Renal or urinary tract malformation (Orphanet:93545), Hereditary steroid-resistant nephrotic syndrome (Orphanet:656), Congenital total pulmonary venous return anomaly (Orphanet:99125)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

23 associations (top):

Study	Trait	p-value
GCST000509_3	Response to citalopram treatment	3.000000e-06
GCST000509_5	Response to citalopram treatment	1.000000e-06
GCST001134_20	White blood cell types	9.000000e-07
GCST003075_72	Cognitive decline rate in late mild cognitive impairment	2.000000e-07
GCST003472_3	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	5.000000e-06
GCST003996_35	Monobrow	2.000000e-19
GCST003999_9	Nose size	3.000000e-09
GCST004070_4	Cerebrospinal P-tau181p levels	8.000000e-08
GCST004611_164	High light scatter reticulocyte count	6.000000e-14
GCST004612_184	High light scatter reticulocyte percentage of red cells	7.000000e-13
GCST004619_14	Reticulocyte fraction of red cells	4.000000e-20
GCST004622_89	Reticulocyte count	8.000000e-22
GCST004780_2	Cortisol levels (saliva)	9.000000e-06
GCST006186_8	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	3.000000e-08
GCST006193_7	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	6.000000e-07
GCST006194_9	Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)	7.000000e-06
GCST006195_94	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	4.000000e-12
GCST009281_5	Microalbuminuria in type 1 diabetes	3.000000e-09
GCST010241_423	Apolipoprotein A1 levels	2.000000e-12
GCST010242_336	HDL cholesterol levels	3.000000e-13
GCST010298_2	Metopic nonsyndromic craniosynostosis	3.000000e-09
GCST012202_6	Distal/Left-sided colorectal cancer	5.000000e-09
GCST012205_6	Distal colorectal cancer	9.000000e-08

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0007710	cognitive decline measurement
EFO:0007679	oppositional defiant disorder measurement
EFO:0007906	synophrys measurement
EFO:0004763	p-tau measurement
EFO:0007986	reticulocyte count
EFO:0005843	cortisol measurement
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006336	diastolic blood pressure
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0008511	metopic craniosynostosis

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D007021	Hypospadias	C12.050.351.875.466; C12.100.500.494.400; C12.200.294.494.400; C12.200.706.516; C12.800.516; C16.131.939.516
D013771	Tetralogy of Fallot	C14.240.400.849; C14.280.400.849; C16.131.240.400.849
C566906	Cakut (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs79085477	Toxicity	3	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	Acute lymphoblastic leukemia;Osteonecrosis

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs79085477	BMP7	3	0.00	1	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases reaction, increases expression, increases secretion, decreases expression	6
Valproic Acid	affects cotreatment, increases expression, affects expression	6
trichostatin A	affects cotreatment, increases expression	3
Resveratrol	affects cotreatment, decreases expression, increases chemical synthesis, increases reaction	3
Tretinoin	decreases expression, increases expression	3
aristolochic acid I	decreases expression, affects cotreatment, decreases reaction, increases expression, increases reaction (+2 more)	2
sodium arsenite	affects methylation, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Decitabine	decreases methylation, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	decreases reaction, increases expression, decreases expression	2
methylmercuric chloride	increases expression	1
propionaldehyde	increases expression	1
bisphenol A	decreases expression	1
arsenite	increases expression	1
afimoxifene	decreases expression, decreases reaction	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
butyraldehyde	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation, increases methylation	1
5,5’-bis(8-(phenylamino)-1-naphthalenesulfonate)	affects binding, increases reaction	1
aristolochic acid II	decreases reaction, increases expression, increases reaction, affects cotreatment	1
pentanal	increases expression	1
octa-2,4,6-trienoic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1

Cellosaurus cell lines

6 cell lines: 3 embryonic stem cell, 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0J5	SEES3-1V human BMP7, clone1	Embryonic stem cell	Male
CVCL_A0J6	SEES3-1V human BMP7, clone2	Embryonic stem cell	Male
CVCL_A0J7	SEES3-1V human BMP7, clone3	Embryonic stem cell	Male
CVCL_D9A5	Ubigene HEK293 BMP7 KO	Transformed cell line	Female
CVCL_SF37	HAP1 BMP7 (-) 1	Cancer cell line	Male
CVCL_XM04	HAP1 BMP7 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

180 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02848157	PHASE4	COMPLETED	Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery
NCT02861950	PHASE4	COMPLETED	Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants?
NCT03902249	PHASE4	COMPLETED	Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair
NCT05708989	PHASE4	WITHDRAWN	Caudal vs. Pudendal Block in Peds GU
NCT05837000	PHASE4	UNKNOWN	Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair
NCT05922605	PHASE4	UNKNOWN	Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias
NCT07121764	PHASE4	COMPLETED	Postoperative Pain Relief in Children: Comparing Caudal Bupivacaine Alone Versus Bupivacaine With Dexmedetomidine for Infra-Umbilical Surgeries Under General Anesthesia
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT01971593	PHASE4	TERMINATED	The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease
NCT01370798	PHASE3	COMPLETED	Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications
NCT04423107	PHASE3	UNKNOWN	Assessment of Postop Hypospadias Pain
NCT04826484	PHASE3	TERMINATED	Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
NCT07197203	PHASE3	NOT_YET_RECRUITING	Comparison of Caudal Block and Sacral Erector Spinae Plane Block With Dexmedetomidine in Pediatric Penile Hypospadias Repair
NCT03277430	PHASE3	UNKNOWN	Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study
NCT00564993	PHASE3	TERMINATED	Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot
NCT05253456	PHASE2	COMPLETED	Modified Second Layer Repair for Distal Penile Hypospadias
NCT00848393	PHASE2	COMPLETED	Measures to Lower the Stress Response in Pediatric Cardiac Surgery
NCT02010905	PHASE2	UNKNOWN	Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
NCT04479371	PHASE1	WITHDRAWN	Liposomal Bupivacaine vs Standard Penile Block for Hypospadias Repair
NCT04115345	PHASE1	COMPLETED	A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).
NCT05694169	PHASE1	TERMINATED	A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
NCT00573066	PHASE1	COMPLETED	Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
NCT01915277	PHASE1	COMPLETED	A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics
NCT04713657	PHASE1	RECRUITING	Beta-blocker Administration for Cardiomyocyte Division
NCT02752308	PHASE2/PHASE3	COMPLETED	Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair
NCT04876976	PHASE2/PHASE3	COMPLETED	Isoamyl 2-Cyanoacrylate in the Urethro-cutaneous Fistula Repair
NCT05093166	PHASE1/PHASE2	TERMINATED	Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure
NCT04196400	EARLY_PHASE1	UNKNOWN	The Role of Local Long Acting Corticosteroid Injection in Hypospadias Surgery.
NCT01762007	Not specified	WITHDRAWN	The Change of the Detrusor Thickness After Hypospadias Repair - Comparison With the Normal Control Group
NCT01875640	Not specified	COMPLETED	Decision Support for Parents Receiving Information About Child’s Rare Disease
NCT02040389	Not specified	COMPLETED	Visual Guidelines and Tutoring in Pediatric Urological Surgery
NCT02096159	Not specified	ACTIVE_NOT_RECRUITING	Prophylactic Antibiotics or Placebo After Hypospadias Repair
NCT02103712	Not specified	COMPLETED	Long Term Outcome of Hypospadias Repair
NCT02162810	Not specified	TERMINATED	Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair
NCT02164682	Not specified	COMPLETED	The Effect of Caudal Block on the Postoperative Complications in Pediatric Patients After Hypospadias Repair
NCT02495090	Not specified	COMPLETED	Hypospadias and Exome: Identification of New Genes for Familial Hypospadias
NCT02497963	Not specified	UNKNOWN	Foreskin Graft Tubularized Incised Plate Urethroplasty vs Tubularized Incised Plate for Primary Hypospadias (FGTIP-TIP)
NCT02512887	Not specified	UNKNOWN	Caudal vs Local Anesthesia in Hypospadias
NCT02593903	Not specified	COMPLETED	Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair
NCT02805491	Not specified	COMPLETED	Influence of Pesticide Exposure on the Occurrence of Hypospadias in Newborns in Picardie